No data available for drug.
DRUG INTERACTION
No drug interaction found for sertindole and .
rivastigmine
may diminish the therapeutic effect of anti-parkinson agents
procyclidine
may diminish the therapeutic effect of anti-parkinson agents
biperiden
may diminish the therapeutic effect of anti-parkinson agents
benztropine
may diminish the therapeutic effect of anti-parkinson agents
levodopa
may diminish the therapeutic effect of anti-parkinson agents
maralixibat
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Sertindole
lenacapavir
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Sertindole
curcumin
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Sertindole
glecaprevir
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Sertindole
caspofungin
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Sertindole
mibefradil
may increase the QTc-prolonging effect of QT-prolonging Agents
fluconazole
may increase the QTc-prolonging effect of QT-prolonging Agents
ritonavir
may increase the QTc-prolonging effect of QT-prolonging Agents
foscarnet
may increase the QTc-prolonging effect of QT-prolonging Agents
sorafenib
may increase the QTc-prolonging effect of QT-prolonging Agents
moexipril
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
voriconazole
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
nelfinavir
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
alfuzosin
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
enzalutamide
CYP3A strong enhancers of the small intestine may reduce the bioavailability of sertindole
domperidone
it increases the effect of QT-prolonging agents
escitalopram
it increases the QTc prolongation of QT-prolonging agents
diltiazem
may enhance the serum concentration of CYP3A4 inhibitors
famprofazone
may enhance the adverse/toxic effect of amphetamines
dexamethasone
It may enhance the metabolism when combined with dexamethasone
dexfenfluramine
serotonergic Agents may enhance the adverse/toxic effect of antipsychotic Agents
methamphetamine
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
metamfetamine
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
phentermine
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
donepezil (Rx)
may enhance the neurotoxic (central) effect of antipsychotic agents
carbaryl
may enhance the neurotoxic (central) effect of antipsychotic agents
rivastigmine
may enhance the neurotoxic (central) effect of antipsychotic agents
rufinamide
may enhance the adverse/toxic effect of antipsychotic agents
brivaracetam
may enhance the adverse/toxic effect of antipsychotic agents
cannabidiol
may enhance the adverse/toxic effect of antipsychotic agents
carbamazepine
may enhance the adverse/toxic effect of antipsychotic agents
cenobamate
may enhance the adverse/toxic effect of antipsychotic agents
magaldrate
antacids may reduce the absorption of antipsychotic agents
omeprazole
antacids may reduce the absorption of antipsychotic agents
rufinamide
may increase the risk of adverse effects of antipsychotic agents
tiagabine
may increase the risk of adverse effects of antipsychotic agents
topiramate
may increase the risk of adverse effects of antipsychotic agents
acetazolamide
may increase the risk of adverse effects of antipsychotic agents
trimethadione
may increase the risk of adverse effects of antipsychotic agents
mibefradil
may enhance the effect of antipsychotic agents
indoramin
may enhance the effect of antipsychotic agents
terazosin
may enhance the effect of antipsychotic agents
atenolol
may enhance the effect of antipsychotic agents
brivaracetam
may enhance the adverse effect of antipsychotic agents
cannabidiol
may enhance the adverse effect of antipsychotic agents
zonisamide
may increase the risk of adverse effect
ezogabine
may increase the risk of adverse effect
mexiletine
may increase the risk of adverse effect
No data available for drug.
DRUG INTERACTION
sertindole
&
No Drug Intearction Found. for sertindole and .
rivastigmine
may diminish the therapeutic effect of anti-parkinson agents
procyclidine
may diminish the therapeutic effect of anti-parkinson agents
biperiden
may diminish the therapeutic effect of anti-parkinson agents
benztropine
may diminish the therapeutic effect of anti-parkinson agents
levodopa
may diminish the therapeutic effect of anti-parkinson agents
maralixibat
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Sertindole
lenacapavir
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Sertindole
curcumin
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Sertindole
glecaprevir
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Sertindole
caspofungin
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Sertindole
mibefradil
may increase the QTc-prolonging effect of QT-prolonging Agents
fluconazole
may increase the QTc-prolonging effect of QT-prolonging Agents
ritonavir
may increase the QTc-prolonging effect of QT-prolonging Agents
foscarnet
may increase the QTc-prolonging effect of QT-prolonging Agents
sorafenib
may increase the QTc-prolonging effect of QT-prolonging Agents
moexipril
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
voriconazole
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
nelfinavir
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
alfuzosin
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
enzalutamide
CYP3A strong enhancers of the small intestine may reduce the bioavailability of sertindole
domperidone
it increases the effect of QT-prolonging agents
escitalopram
it increases the QTc prolongation of QT-prolonging agents
diltiazem
may enhance the serum concentration of CYP3A4 inhibitors
famprofazone
may enhance the adverse/toxic effect of amphetamines
dexamethasone
It may enhance the metabolism when combined with dexamethasone
dexfenfluramine
serotonergic Agents may enhance the adverse/toxic effect of antipsychotic Agents
methamphetamine
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
metamfetamine
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
phentermine
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
donepezil (Rx)
may enhance the neurotoxic (central) effect of antipsychotic agents
carbaryl
may enhance the neurotoxic (central) effect of antipsychotic agents
rivastigmine
may enhance the neurotoxic (central) effect of antipsychotic agents
rufinamide
may enhance the adverse/toxic effect of antipsychotic agents
brivaracetam
may enhance the adverse/toxic effect of antipsychotic agents
cannabidiol
may enhance the adverse/toxic effect of antipsychotic agents
carbamazepine
may enhance the adverse/toxic effect of antipsychotic agents
cenobamate
may enhance the adverse/toxic effect of antipsychotic agents
magaldrate
antacids may reduce the absorption of antipsychotic agents
omeprazole
antacids may reduce the absorption of antipsychotic agents
rufinamide
may increase the risk of adverse effects of antipsychotic agents
tiagabine
may increase the risk of adverse effects of antipsychotic agents
topiramate
may increase the risk of adverse effects of antipsychotic agents
acetazolamide
may increase the risk of adverse effects of antipsychotic agents
trimethadione
may increase the risk of adverse effects of antipsychotic agents
mibefradil
may enhance the effect of antipsychotic agents
indoramin
may enhance the effect of antipsychotic agents
terazosin
may enhance the effect of antipsychotic agents
atenolol
may enhance the effect of antipsychotic agents
brivaracetam
may enhance the adverse effect of antipsychotic agents
cannabidiol
may enhance the adverse effect of antipsychotic agents
zonisamide
may increase the risk of adverse effect
ezogabine
may increase the risk of adverse effect
mexiletine
may increase the risk of adverse effect
medtigo
Action and Spectrum
Drug Interaction
Adverse Reaction
Black Box Warning
Contraindication / Caution
Pregnancy / Lactation
Pharmacology
Adminstartion
Patient Information Leaflet